[go: up one dir, main page]

AU2001244711A1 - Tlr/cd14 binding inhibitor - Google Patents

Tlr/cd14 binding inhibitor

Info

Publication number
AU2001244711A1
AU2001244711A1 AU2001244711A AU4471101A AU2001244711A1 AU 2001244711 A1 AU2001244711 A1 AU 2001244711A1 AU 2001244711 A AU2001244711 A AU 2001244711A AU 4471101 A AU4471101 A AU 4471101A AU 2001244711 A1 AU2001244711 A1 AU 2001244711A1
Authority
AU
Australia
Prior art keywords
tlr
binding inhibitor
inhibitor
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244711A
Inventor
Shouji Furusako
Sadao Mori
Kamon Shirakawa
Tomohiro Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/806,158 external-priority patent/US6916628B1/en
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Publication of AU2001244711A1 publication Critical patent/AU2001244711A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001244711A 2000-03-31 2001-04-02 Tlr/cd14 binding inhibitor Abandoned AU2001244711A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2000099617 2000-03-31
JP2000-99617 2000-03-31
US09/806,158 US6916628B1 (en) 1999-09-17 2000-09-18 Method for the measurement of soluble CD14 proteins separately
JP2000-356719 2000-11-22
JP2000356719 2000-11-22
US09806158 2001-03-28
PCT/JP2001/002869 WO2001072993A1 (en) 2000-03-31 2001-04-02 Tlr/cd14 binding inhibitor

Publications (1)

Publication Number Publication Date
AU2001244711A1 true AU2001244711A1 (en) 2001-10-08

Family

ID=27342946

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244711A Abandoned AU2001244711A1 (en) 2000-03-31 2001-04-02 Tlr/cd14 binding inhibitor

Country Status (4)

Country Link
EP (1) EP1275713A4 (en)
AU (1) AU2001244711A1 (en)
CA (1) CA2404511A1 (en)
WO (1) WO2001072993A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125272A1 (en) * 2001-11-19 2003-07-03 Karras James G. Antisense modulation of toll-like receptor 4 expression
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6916628B1 (en) 1999-09-17 2005-07-12 Mochida Pharmaceutical Co., Ltd. Method for the measurement of soluble CD14 proteins separately
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
ES2340266T3 (en) 2002-11-12 2010-06-01 Mochida Pharmaceutical Co., Ltd. ANALYSIS KIT FOR CD14 HUMAN LOW MOLECULAR WEIGHT AND ANTIBODY.
US7608684B2 (en) 2002-11-12 2009-10-27 Mochida Pharmaceuticals Co., Ltd. Soluble CD14 antigen
CN1787741B (en) * 2003-05-15 2011-08-17 唐纳士公司 Methods and compositions for the prevention and treatment of sepsis
AU2003271835A1 (en) * 2003-06-06 2005-01-04 Avecia Limited Process for the separation of proteins
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005026209A2 (en) 2003-09-11 2005-03-24 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
JP2005137333A (en) * 2003-11-10 2005-06-02 Japan Science & Technology Agency Screening method using TBK1 knockout mouse
EP1746104B1 (en) 2004-05-11 2013-03-20 Mochida Pharmaceutical Co., Ltd. Novel soluble cd14 antigen
EP1889908A4 (en) 2005-06-03 2012-04-25 Mochida Pharm Co Ltd Anti-cd14 antibody-fused protein
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
GB0815673D0 (en) * 2008-08-28 2008-10-08 Univ Cardiff Peptides
EP2328911A4 (en) 2008-09-22 2012-03-14 Cedars Sinai Medical Center HUMAN MD-2 IN SHORT FORM AS NEGATIVE REGULATOR OF TOLL-4 TYPE RECEIVER SIGNALING
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
US8765370B2 (en) * 2009-06-11 2014-07-01 Scinopharm Taiwan, Ltd Inhibition-based high-throughput screen strategy for cell clones
CN116444673B (en) * 2023-06-14 2023-09-15 北京汇智和源生物技术有限公司 Humanized membrane CD14 monoclonal antibody and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543303A (en) * 1988-11-28 1996-08-06 Goyert; Sanna M. Recombinant myelomonocytic differentiation antigen CD14
US5705398A (en) * 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
WO1996008272A1 (en) * 1994-09-16 1996-03-21 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
CN1322214A (en) * 1998-05-27 2001-11-14 吉马生物技术有限公司 Induction of Avidin and Antibiotic Polypeptides by LAIT/sCD14-Protein
JP2000086699A (en) * 1998-09-07 2000-03-28 Seikagaku Kogyo Co Ltd New monoclonal antibody for recognizing cell surface antigen cd14

Also Published As

Publication number Publication date
WO2001072993A1 (en) 2001-10-04
CA2404511A1 (en) 2001-10-04
EP1275713A1 (en) 2003-01-15
EP1275713A4 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
AU2001258771A1 (en) -secretase inhibitors
AU2001262847A1 (en) Language-understanding
AU2001244711A1 (en) Tlr/cd14 binding inhibitor
AU2000267458A1 (en) Hypercomputer
AU2001254546A1 (en) Aminopiperidines
AU2001220246A1 (en) Neckphone
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001258349A1 (en) Bisacylguanidine
AU2001279754A1 (en) Indoloquinazolinones
AU2001258924A1 (en) Microsatellite-aflp
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors
AU2001282644A1 (en) Case
AU2001257009A1 (en) Enhanced hyperlink
AU2001284173A1 (en) Calycins
AU2001275014A1 (en) Imidazoloisoquinolines
AUPQ542900A0 (en) Microprocessor
AU2001256521A1 (en) Golf-putters
AU2001256287A1 (en) 2-phenyl-2h-pyridazine-3-ones
AU2001263003A1 (en) Carboxyalkylether-acat inhibitor combinations
AU2001262197A1 (en) 2-phenyl-2h-pyridazine-3-ones
AU2845301A (en) 4-aryl-1-difluoromethoxyimidazole
AU2001267941A1 (en) Sailcraft
AU2001277651A1 (en) Toilet-bidet
GB0004895D0 (en) Inhibitor